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ABSTRACT
According to recent studies, adipose tissue secretes a large number of bioactive proteins, which affect the whole 
body metabolism. The amount of adipose tissue is the main factor that explains metabolic disorders; 
however, obesity is not necessarily the result of increased body weight. Interestingly, there is a subgroup 
of patients with normal weight and high-risk metabolic profile. Consequently, they are significantly more 
likely to have metabolic disorders or cardiovascular disease (CVD). Conversely, some individuals, called 
metabolically healthy obese (MHO), demonstrate a favourable metabolic profile despite having high BMI 
index and excessive adipose tissue.
The aim of this paper is to review recent studies about obesity phenotypes. Better understanding of differences 
between metabolically obese normal-weight (MONW) and MHO may improve the therapy and treatment 
of metabolic health in all obese patients. Equally importantly, it may lead to an increase in early detection 
of individuals with metabolic disorders, regardless of their body mass value or BMI.
Key words: adipose tissue, obesity phenotypes, metabolically healthy obese, visceral adipose tissue, 
metabolically obese normal-weight
Med Res J 2016; 1, 3: 95–99
Corresponding author: 
Paulina Cembrowska 
Department of Laboratory Medicine,  
Nicolaus Copernicus University,  
Collegium Medicum in Bydgoszcz 
Skłodowskiej-Curie 9 St. 
85–094 Bydgoszcz, Poland 
E-mail: paulina.cembrowska@wp.pl
Medical Research Journal 2016;
Volume 1, Number 3, 95–99
10.5603/MRJ.2016.0016
Copyright © 2016 Via Medica
ISSN 2451–2591
Introduction
It is becoming increasingly difficult to ignore the fact 
that obesity is the epidemic of our century and one of 
the major public health concerns. This medical condi-
tion contributes to increased mortality. Modern lifestyle 
leads to the development of metabolic disorders and ec-
topic accumulation of adipose tissue, which are closely 
associated with the growth in the prevalence of type 2 
diabetes, cardiovascular diseases, non-alcoholic fatty 
liver disease, dyslipidaemia, and hypertension [1–5]. 
Furthermore, treatment of obesity and obesity-related 
complications generates high costs. Thus, the aim of 
medicine nowadays is to identify those who are at risk 
of developing obesity and metabolic disorders, and to 
try to prevent secondary clinical complications [6–8].
At present it appears to be difficult to prepare consis-
tent guidelines for obesity treatment. According to many 
studies, obesity is not only connected with increased 
body weight and value of BMI [5, 9]. The interesting 
finding is that there are significant differences in the met-
abolic profiles between people assigned to the same 
categories of BMI. It shows that the major problems 
are composition and distribution of body fat instead of 
the amount of adipose tissue [5, 10–12]. Therefore, it 
became essential to distinguish the particular type of 
accumulated fat mass. Visceral fat has been considered 
as an active endocrine organ that may contribute to the 
development of many metabolic disorders. An excess 
of this type of fat is more disquieting [5, 10, 13, 14]. 
Subcutaneous fat does not have as important an impact 
on metabolic parameters in humans as visceral fat. 
However, adipose tissue accumulated in this depot has 
a large volume and secretory properties that affect the 
balance of our body [12, 13, 14]. 
The purpose of this paper is to review the most re-
cent information about obesity phenotypes. Due to the 
fact that an excess of visceral fat may not significantly 
affect the BMI and waist circumference measurement, 
there is a subgroup of obesity which is characterized 
by normal weight and an increase in the possibility of 
developing type 2 diabetes, dyslipidaemia, and liver 
fat [5, 9, 15]. On the other hand, not all obese individ-
uals demonstrate adverse metabolic effects, and their 
cardio-metabolic risk may be even lower than for the 
above-mentioned group [6, 16, 17].
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Visceral and subcutaneous  
adipose tissue
The term "obesity" is generally used to describe the 
excess accumulation of body fat, frequently measured 
by BMI or waist circumference value [9, 14]. However, 
many studies have established that the BMI formula is 
only a mathematical estimate, useful in population stud-
ies. According to recent investigations, it is necessary 
to assess the composition and distribution of body fat, 
rather than to simply measure the body weight. There-
fore, there has been increasing interest in the role of 
adipose tissue in lipid and glucose metabolism. Due 
to the fact that these tissues secrete a large number 
of bioactive proteins and pro-inflammatory cytokines, 
adipocyte metabolism appears to be a major cause of 
the development of metabolic disorders [7, 9, 14, 18]. 
Thus, it is crucial to evaluate the regional distribution of 
fat and ectopic fat depots. The content of visceral and 
subcutaneous adipose tissue seems to be the main 
issue to explain the metabolic abnormalities in individ-
uals representing various obesity phenotypes, mainly 
in the context of secretion of different adipokines and 
other bioactive substances [14, 19].
Therefore, it seems that there is a strong correlation 
between an excess of adipose tissue in the central 
part of the body and the occurrence of metabolic dis-
orders. Generally, the risk of metabolic syndrome is 
lower when body fat is stored in the peripheral part of 
the body [13, 19–21]. Visceral adipose tissue (VAT) is 
stored in the abdominal cavity and surrounds internal 
organs, while subcutaneous adipose tissue is mainly 
located peripherally (Fig. 1) [13, 19].
According to Bays et al., a positive energy balance 
leads to an excess of free fatty acids, which are accu-
mulated in subcutaneous adipose tissue. However, an 
imbalance of energy may also lead to fat accumulation 
in ectopic depots as visceral adipose tissue, surround-
ing the heart and vasculature [19, 22].
It is important to distinguish visceral and subcuta-
neous adipose tissue in connection with the expression 
of different adipokines. Visceral adiposity is associated 
with an adverse cardiometabolic profile, including 
inflammation, insulin resistance, and myocardial dys-
function. Due to the fact that VAT surrounds abdominal 
organs and is located near the portal vein, substances 
secreted by this tissue are transported throughout the 
organism [19, 20]. The excess of visceral fat supports 
pathological vascular changes by secretion of pro-in-
flammatory and pro-atherosclerotic mediators, such 
as interleukin 6 (IL-6), plasminogen activator inhibi-
tor-1 (PAI-1), and glucocorticoids, which account for the 
development of cardiovascular diseases such as coro-
nary artery disease and cardiac dysfunction [19–21, 23]. 
It has also been observed that increased concentrations 
of C-reactive protein (CRP), tumour necrosis factor 









(TNF-a), and interleukin 18 (Il-18) lead to a state of 
chronic low-grade inflammation [19, 21]. Greater insulin 
resistance has been observed in patients with visceral 
fat obesity. Jung et al. point out that increasing secre-
tion of monocyte chemotactic protein (MCP-1), TNF-a, 
interleukin 1 (Il-1), Il-6, and interleukin 8 (Il-8) contributes 
to development of type 2 diabetes. Matsuzawa et al. 
have also reported that VAT reduction contributes to 
decreasing blood pressure [10, 23].
The main role of subcutaneous adipose tissue (SAT) 
is to accumulate an excess of energy during positive ca-
loric balance, which may be metabolically ‘protective’ if 
proliferation and differentiation of fat cells proceed prop-
erly. In contrast to visceral fat, it secretes adiponectin, 
which has a protective and anti-inflammatory role [19, 21]. 
In many studies it has been suggested that the excess 
of SAT has a stronger correlation with insulin sensitivity 
than VAT [13]. Furthermore, Britton et al., in their review, 
draw our attention to the ability of subcutaneous fat to 
promote angiogenesis and a greater capillary network 
in comparison to visceral fat, which leads to a higher 
blood flow [22].
In summary, researchers have shown recently that 
adipose tissue is not only for energy storage, but also it 
affects the whole body metabolism through a large num-
ber of bioactive proteins. Due to differences between 
subcutaneous and visceral adipose tissue, it is crucial 
to evaluate the composition and distribution of body fat 
instead of the amount of adipose tissue. The screening 
of body fat distribution may become a useful tool in the 
prevention of obesity-related diseases, and evaluation 
and proper classification of the obese [13, 14, 20].
Obesity phenotypes
In the 1980s Ruderman et al. observed and first 
described some non-obese individuals with metabolic 
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Table 1. Obesity phenotypes 









BMI [kg/m2] 18.5–25 18.5–25 > 30 > 30
Fat mass (%) M > 23.5, W > 29.2 > 30 >30 > 30
Fat distribution Low lean body mass, 
higher than norm total body 
fat
High content of visceral 
adipose tissue, low lean 
body mass and ectopic fat
Less visceral and ectopic 
fat than MUO
Fat cumulated mostly in 




Higher fasting glucose level Low insulin sensitivity Proper sensitivity of insulin Insulin resistant, diabetes
Lipid profile Improper lipid 
concentrations
Concentrations of hdl-
cholesterol low and 
triglycerides high
Proper Improper lipid 
concentrations
Inflammation Early inflammatory 
status, higher values of 
proinflammatory cytokines
Early inflammatory status, 
the increased levels of 
inflammation biomarkers




Higher risk of metabolic 
syndrome, hypertension 
(M), CVD (W)





BMI — body mass index; M — man; W — woman; CVD — cardiovascular disease
abnormalities and obese people with a proper metabolic 
profile. Recent research has demonstrated that individu-
als classified on the basis of body weight or BMI do not 
always exhibit the same risk of cardiovascular diseases 
(CVD) and metabolic syndrome. According to Lorenzo 
et al., currently there are four phenotypes of obesity [5]:
 — normal-weight obese (NWO);
 — metabolically obese normal-weight (MONW);
 — metabolically healthy obese (MHO);
 — metabolically unhealthy obese (MUO).
However, there are still no strictly defined diag-
nostic criteria for phenotypes of obesity. Furthermore, 
researchers are mostly focused on MONW and MHO 
groups, as the potential incorrect classification of these 
individuals — MONW as healthy and MHO as ordinary 
obese. Individuals belonging to NWO and MONW both 
represent a state of increased body fat content with 
normal weight; nevertheless, there are minor differences 
between their representatives [5, 25]. The table below 
illustrates the comparison of obesity phenotypes ac-
cording to current literature (Tab. 1) [5, 25–27].
Normal-weight obese (NWO)
Individuals belonging to this phenotype have 
normal BMI (18.5–25 kg/m2); however, their body fat 
percentage is above the norm (men — 23.5% and 
women — 29.2%), which contributes to a higher risk of 
metabolic abnormalities [5, 25]. According to Lorenzo 
et al., NWO individuals may demonstrate higher fasting 
glucose levels, hypertension, disorders in lipid profiles, 
early inflammatory status, and higher oxidative stress 
in comparison to healthy normal-weight individuals [5]. 
However, NWO patients do not develop all of the factors 
that are needed for recognition of metabolic syndrome 
in contrast to metabolically obese normal-weight indi-
viduals [5].
Many studies have shown that NWO individuals have 
elevated plasma concentrations of pro-inflammatory 
cytokines in comparison to metabolically healthy nor-
mal-weight people. Increased concentrations of TNF-a, 
Il-8, and IL-6 have been observed in this group. These 
data suggest the occurrence of the early inflammatory 
response, which may be due to the increased content 
of fat mass [25]. Renzo et al. demonstrated that NWO 
patients have a higher level of oxidative stress markers, 
compared with the obese. The oxidative stress may be 
closely related to vascular dysfunction and the devel-
opment of CVD [25, 27–29].
Metabolically obese normal-weight (MONW)
Representatives of this subgroup possess normal 
weight (BMI between 18.5 and 25 kg/m2); however, 
they have a high content of visceral adipose tissue and 
fat mass, as well as low lean body mass and ectopic 
fat distribution [21, 25]. According to Thomas et al., 
these individuals demonstrate a higher ratio of visceral 
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and subcutaneous abdominal adipose tissue [21]. Ac-
cording to Shea et al., individuals with normal weight 
belonging to this phenotype have been associated with 
an increased waist circumference and body fat [25, 30].
MONW is a group with a higher risk of developing 
metabolic syndrome, which is caused by the occurrence 
of low insulin sensitivity, low HDL-cholesterol, and high 
triglycerides concentrations. Moreover, they exhibited 
increased levels of inflammatory biomarkers and a high-
er risk of the occurrence of diabetes and cardiovascular 
disease. In fact, MONW individuals represent metabolic 
abnormalities typical of obesity [14, 31].
It seems to be difficult to determine the prevalence 
of MONW, due to the lack of a standardised definition of 
this phenotype. Some researchers evaluate that 23.5% 
of normal-weight adults represent the metabolically 
obese normal-weight subgroup, when metabolic syn-
drome criteria are used. However other data suggest 
that this phenotype prevalence is 3–28%, depending 
on the used definition of metabolic risk [26, 32, 33]. 
Regarding race, there have been distinctions in preva-
lence of MONW phenotype — some studies have shown 
that Asians are more likely to be MONW than typically 
obese. According to Mathew et al., Chinese people have 
a higher risk of intra-abdominal obesity and ectopic 
accumulation of fat, even if they tend to be lean [32]. 
Generally, it is recommended that MONW individu-
als modify their lifestyle by a suitable diet and exercise 
program supported by the appropriate therapy for 
metabolic disorders [34].
Metabolically healthy obese (MHO)
The metabolically healthy obese subgroup was 
first featured in 1982 and represents 10–30% of the 
whole group of obese; however, until now there has 
been no standardised definition of this phenotype [6, 
8, 35]. According to BMI classification, individuals 
belonging to this subgroup are obese, with BMI over 
30 kg/m2, but they do not have metabolic abnor-
malities. Although they have the excess of adipose 
tissue, they possess less visceral and ectopic fat with 
low hepatic steatosis. Consequently, their metabolic 
profiles are favourable: no hypertension, high insulin 
sensitivity, and correct lipid and hormonal profile. 
However, MHO individuals display other obesity-re-
lated complications: chronic pain, sleep problems, 
pulmonary disease, articulation and postural prob-
lems, etc. [1, 6, 7, 36]. Moreover, Samocha-Bonet et 
al. suggest that 30% of MHO people may be transi-
tioned to the metabolically unhealthy obese group, 
while others propose as many as 50% [8]. Thus, 
longitudinal studies seem to be crucial to evaluate 
the possibility of developing metabolic complications 
typical of obesity [32].
Surprisingly, MHO individuals frequently represent 
a high fitness level, which is associated with less visceral 
and intrahepatic fat content [6]. This may explain the fact 
that the lifestyle and diet change have no effect on BMI 
modifications in these subjects [32, 37]. Other studies 
suggest that the occurrence of the MHO phenotype is 
not related to physical activity, alcohol consumption, or 
diet. However, some researches point out smoking and 
lower education levels as potential risk factors [32, 38].
According to different data, MHO phenotype is asso-
ciated with lower plasma concentrations of TNF-a, IL-6, 
and CRP, which is related to a low degree of inflamma-
tion. It can also display a favourable lipid profile – high 
concentration of HDL cholesterol, high LDL level, and 
low triglycerides [32, 39].
Messier et al., in their study, showed lower con-
centrations of hepatic enzymes (alkaline phosphatase, 
alanine aminotransferase, aspartate aminotransferase, 
g-glutamyl transferase) in MHO plasma in comparison 
with the obese with risk of metabolic syndrome [40].
Metabolically unhealthy obese (MUO)
The metabolically unhealthy obese are character-
ised by BMI over 30 kg/m2 and body fat percentage 
over 30%. In addition, excess fat mass is cumulated 
mostly in visceral adipose tissue, which leads to the 
development of metabolic syndrome, diabetes, car-
diovascular disease, and increased mortality. There 
are defined diagnostic criteria and guidelines for these 
patients [5]. Individuals representing MUO phenotype 
are simply recognised by the physician or they report 
themselves for medical support. 
Conclusions
The crucial finding of the presented review is the fact 
that individuals belonging to all four obesity phenotypes 
are at risk of developing obesity-related diseases; how-
ever, NWO and MONW individuals are mostly unaware 
that they are in the risk group. Frequently screening 
tests are based on anthropometric measures, which is 
associated with misclassification of these individuals.
The second significant finding to emerge from this 
review is that individuals representing both phenotypes 
— metabolically healthy obese and metabolically obese 
normal-weight — have the same risk of disturbances 
related to obesity, and they require medical care. Al-
though MHO individuals do not demonstrate metabolic 
disorders, they also need medical attention and peri-
odic weight management because of obesity-related 
complications. 
Therefore, it seems that medical education may be 
crucial in the prevention of development of obesity and 
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metabolic disorders. There is a definite need for new 
guidelines for obesity treatment dependent on pheno-
type, which allows an estimation of the inflammatory 
and metabolic profile of the patient, independently of 
BMI and body size.
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